RxDoctor Payments Data

Alejandra Bonilla-Rojas

Family · Brawley, CANPI 1669019618

Payments from drug & device makers

$2,638in general payments, 2019–2025

Across 151 payments — averaging $17.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$379
  • Novo Nordisk$297
  • AstraZeneca$276
  • Sanofi-aventis U.S. LLC$198
  • Lilly USA, LLC$186
  • GSK$172
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$2,638100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,638 in reported general payments places this provider in the 85th percentile of 10,634 family providers in California.

See all family providers in California

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide130$133,923
OzempicSemaglutide114$114,474
RybelsusSemaglutide58$84,847
LinzessLinaclotide119$81,758
FarxigaDapagliflozin Propanediol85$76,071
JardianceEmpagliflozin66$57,738
VascepaIcosapent Ethyl105$53,710
JanuviaSitagliptin Phosphate51$49,998
Soliqua 100-33Insulin Glargine/Lixisenatide54$38,570
TrulicityDulaglutide34$33,589
EliquisApixaban27$32,693
Icosapent Ethyl78$23,060
EntrestoSacubitril/Valsartan31$22,887
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog42$19,999
MyrbetriqMirabegron32$19,919

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$297$199,321172 claims
Lilly USA, LLCMounjaro, Trulicity$186$167,511164 claims
AbbVieLinzess$81$81,758119 claims
Boehringer IngelheimJardiance, Tradjenta$107$76,45985 claims
AstraZenecaFarxiga$276$76,07185 claims
MerckJanuvia, Janumet$132$66,10566 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$198$38,57054 claims
PfizerEliquis$62$32,69327 claims
NovartisEntresto$19$22,88731 claims
Astellas Pharma US IncMyrbetriq$30$19,91932 claims
Johnson & JohnsonXarelto$379$16,06314 claims
GSKTrelegy Ellipta$172$8,68914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,634 family providers in California.

Other family in Brawley

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →